Literature DB >> 11549851

Different effects of cyclosporine a and FK506 on potassium transport systems in MDCK cells.

S Aker1, P Heering, E Kinne-Saffran, C Deppe, B Grabensee, R K Kinne.   

Abstract

BACKGROUND: Hyperkalemia and metabolic acidosis are common manifestations in patients receiving the immunosuppressive agent cyclosporine A (CsA) and the recently introduced FK506. We compared the acute toxic and antiproliferative effects as well as the effects on the transport activity of Na(+)/K(+)-ATPase and Na(+)/K(+)/2Cl(-) cotransporter of CsA and FK506 in an established cell line of distal/collecting tubule origin (MDCK cells).
METHODS: MDCK cells were exposed to various concentrations of CsA or FK506 and the effects on cell viability (MTT test and neutral red uptake), plasma membrane integrity (lactate dehydrogenase (LDH) release) and cell proliferation (bromodeoxyuridine (BrdU) incorporation) were compared. For transport studies, after confluence, MDCK cells were exposed to CsA or FK506 for 48 h in the presence and absence of aldosterone. Ouabain- and bumetanide-sensitive (86)Rubidium uptake measurements were used to study the activity of the Na(+)/K(+)-ATPase and Na(+)/K(+)/2Cl(-) cotransporter at the surface of intact cells.
RESULTS: After 24 h of exposure CsA reduced the number of viable cells to 50% at 30 microM, whereas for FK506 2-3 times higher concentrations had to be employed. Similarly, LDH release was stimulated tenfold by 30 microM CsA but only fourfold by 70 microM FK506. In contrast, DNA synthesis was affected at lower concentrations of FK506 than of CsA. In cells treated for 24 h BrdU incorporation was significantly inhibited by 3 microM FK506, whereas a similar inhibition required 10 microM CsA. The transport activity of Na(+)/K(+)-ATPase and of Na(+)/K(+)/2Cl(-) cotransporter were significantly decreased (37 and 63%, respectively) on CsA administration (8 microM). In CsA-treated cells the K(+) channel blockers barium (1 mM), TEA (10 mM) and quinine (1 mM) did not further inhibit the transport activities suggesting that CsA might also act via inhibition of K(+) channels. FK506 at 8 microM had no effect on Na(+)/K(+)-ATPase transport activity but stimulated Na(+)/K(+)/2Cl(-) cotransporter activity by 59%. The stimulatory effect was abolished by K(+) channel blockers indicating that recycling of K(+) might increase by FK506. The simultaneous presence of aldosterone (5 microM) protected the cells from the inhibitory effect of CsA on Na(+)/K(+)-ATPase and Na(+)/K(+)/2Cl(-) cotransporter activity. The stimulatory effect of FK506 on the Na(+)/K(+)/2Cl(-)cotransporter activity was completely abolished in the presence of aldosterone.
CONCLUSIONS: Both CsA and FK506 showed acute toxicity in MDCK cells in vitro with the effects of FK506 being less pronounced. CsA and FK506 had different effects on the in vivo transport rates of the Na(+)/K(+)-ATPase and the Na(+)/K(+)/2Cl(-) cotransporter; CsA inhibited the activity of the Na(+)/K(+)-ATPase and the Na(+)/K(+)/2Cl(-) cotransporter whereas FK506 stimulated the activity of Na(+)/K(+)/2Cl(-) cotransporter. These effects were abolished by the application of aldosterone. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11549851     DOI: 10.1159/000052629

Source DB:  PubMed          Journal:  Exp Nephrol        ISSN: 1018-7782


  10 in total

1.  Fludrocortisone as a new tool for managing tubulopathy after pediatric renal transplantation: a series of cases.

Authors:  Justine Bacchetta; Odile Basmaison; Anne-Laure Leclerc; Aurélia Bertholet-Thomas; Pierre Cochat; Bruno Ranchin
Journal:  Pediatr Nephrol       Date:  2014-06-09       Impact factor: 3.714

2.  Polarized expression of Tamm-Horsfall protein by renal tubular epithelial cells activates human granulocytes.

Authors:  B Kreft; W J Jabs; T Laskay; M Klinger; W Solbach; S Kumar; G van Zandbergen
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

3.  Different effects of CsA and FK506 on aquaporin-2 abundance in rat primary cultured collecting duct cells.

Authors:  Markus M Rinschen; Jens Klokkers; Hermann Pavenstädt; Ute Neugebauer; Eberhard Schlatter; Bayram Edemir
Journal:  Pflugers Arch       Date:  2011-07-20       Impact factor: 3.657

4.  Effects of calcineurin inhibitors on sodium excretion in recipients of allogeneic hematopoietic stem cell transplantation.

Authors:  Masuho Saburi; Sumiko Kohashi; Jun Kato; Yuya Koda; Masatoshi Sakurai; Takaaki Toyama; Taku Kikuchi; Daiki Karigane; Sayako Yuda; Yusuke Yamane; Risa Hashida; Ryohei Abe; Tomonori Nakazato; Junichi Hirahashi; Masao Ogata; Shinichiro Okamoto; Takehiko Mori
Journal:  Int J Hematol       Date:  2017-05-17       Impact factor: 2.490

Review 5.  Pathogenesis of calcineurin inhibitor-induced hypertension.

Authors:  Ewout J Hoorn; Stephen B Walsh; James A McCormick; Robert Zietse; Robert J Unwin; David H Ellison
Journal:  J Nephrol       Date:  2012 May-Jun       Impact factor: 3.902

Review 6.  Adverse effects of immunosuppression in pediatric solid organ transplantation.

Authors:  Kristine S Schonder; George V Mazariegos; Robert J Weber
Journal:  Paediatr Drugs       Date:  2010       Impact factor: 3.022

Review 7.  Electrolyte and Acid-base disturbances induced by clacineurin inhibitors.

Authors:  Chang Hwa Lee; Gheun-Ho Kim
Journal:  Electrolyte Blood Press       Date:  2007-12-31

8.  Fludrocortisone therapy in renal transplant recipients with persistent hyperkalemia.

Authors:  K Marfo; D Glicklich
Journal:  Case Rep Transplant       Date:  2012-09-16

9.  Electrolytes Disturbance and Cyclosporine Blood Levels among Kidney Transplant Recipients.

Authors:  B Einollahi; E Nemati; Z Rostami; M Teimoori; A R Ghadian
Journal:  Int J Organ Transplant Med       Date:  2012

10.  Tacrolimus-Induced Type IV Renal Tubular Acidosis following Liver Transplantation.

Authors:  Christopher Schmoyer; Suraj Mishra; Frank Fulco
Journal:  Case Reports Hepatol       Date:  2017-07-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.